Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia

NCT ID: NCT01354678

Last Updated: 2020-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomised placebo-controlled study of efficiency and safety of bone marrow mononuclear cells transplantation by intramyocardial multiple precision injection in ischemic heart failure patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The increase of prevalence of heart failure in human population requires to develop new and effective methods of treatment. One of them is stem cells transplantation into a myocardial tissue, which cause the improvement of contractility, myocardial remodelling after myocardial infarction (MI), dilated cardiomyopathy, etc. Use of autologous stem cells does not require of immunosuppressive therapy and does not correlate with some ethical problems. Clinical application of mesenchymal stem cells always requires a step of culturing, which is associated with increased risk of contamination Therefore haemopoietic stem cells, endothelial progenitor cells or mononuclear bone marrow cells are often used to be transplant for treatment of heart failure (HF) patients.Using NOGA XP Cardiac Navigation System improves specificity of transplantations, that is decisive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group of bone marrow cell therapy

Group Type ACTIVE_COMPARATOR

NOGA XP Cardiac Navigation System

Intervention Type PROCEDURE

Intramyocardial multiple precision injection of bone marrow mononuclear cells

group of sham therapy

Group Type SHAM_COMPARATOR

NOGA XP Cardiac Navigation System

Intervention Type PROCEDURE

Intramyocardial multiple precision injection with placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOGA XP Cardiac Navigation System

Intramyocardial multiple precision injection of bone marrow mononuclear cells

Intervention Type PROCEDURE

NOGA XP Cardiac Navigation System

Intramyocardial multiple precision injection with placebo

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cordis Corporation's Biologics Delivery Systems Cordis Corporation's Biologics Delivery Systems

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with coronary artery disease (CAD) and HF II-III NYHA class
* MI more than 6 months before the study
* LVEF less than 35%
* absence of indication to coronary revascularization
* optimal pharmacological therapy no less than 8 weeks
* heart transplantation is contraindicated
* patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)
* patients giving informed consent

Exclusion Criteria

* acute coronary syndrome
* coronary revascularization less than 6 months
* patients requiring surgical correction of post-MI aneurism
* LV wall thickness less than 5 mm in site of possible injection
* patients with CRT implanted within 3 month before cells injection
* clinically significant associated diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eugene V Shlyakhto, Prof

Role: PRINCIPAL_INVESTIGATOR

Almazov Federal Heart, Blood and Endocrinology Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Almazov Federal National Medical Research Centre

Saint Petersburg, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IMPI-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Progenitor Cell Therapy in Dilative Cardiomyopathy
NCT00284713 COMPLETED PHASE1/PHASE2
Autologous Cell Therapy for Ischemic Heart Failure
NCT01353690 TERMINATED PHASE1/PHASE2
Cell Therapy in Myocardial Infarction
NCT00350766 TERMINATED PHASE2/PHASE3